Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06356272 · ClinicalTrials.gov registry record
Oropharynx (OPX) Biomarker Trial
A clinical trial of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 440
- Enrollment target
- 1
- Study location
NCT06356272 is a study of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 440 participants, above the 399-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06356272, a study of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 440 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2029-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06356272
The ClinicalTrials.gov registry entry for NCT06356272 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 399-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (10% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06356272 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06356272 about?
NCT06356272 is a clinical study titled "Oropharynx (OPX) Biomarker Trial". The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
What is the current status of trial NCT06356272?
This trial is currently recruiting. The enrollment target is 440 participants. The study started on 2019-11-15. Estimated completion is 2029-11-30.
What conditions does trial NCT06356272 study?
This clinical trial studies the following conditions: Head and Neck Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06356272?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06356272?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06356272 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
RECRUITING · NA
-
Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
RECRUITING · NA
Explore more on PlainTrial
Head and Neck Carcinoma
All registered trials for this condition
Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.